Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health.

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

Many proposals to reform the PBM industry miss the forest for the trees, experts said this week. Instead, Congress should go ...

Thimerosal, targeted by activists who claim it’s linked to autism, shouldn't be used in vaccines given in the U.S. this ...

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.

The biotech, which earlier this year laid off nearly all of its staff, also announced a PIPE that will hand it $175 million ...

Bill Meury, who shepherded Karuna and Anthos to multibillion-dollar buyouts, will take over Incyte, a successful drug ...